Contrasting HCW Biologics (HCWB) & Its Rivals

HCW Biologics (NASDAQ:HCWB – Get Rating) is one of 996 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare HCW Biologics to related companies based on the strength of its earnings, dividends, analyst recommendations, profitability, risk, valuation and institutional ownership.

Insider & Institutional Ownership

1.8% of HCW Biologics shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 44.0% of HCW Biologics shares are owned by company insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for HCW Biologics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	0	0	3	0	3.00
HCW Biologics Competitors	4346	15319	41771	733	2.63

HCW Biologics presently has a consensus price target of $7.00, suggesting a potential upside of 354.55%. As a group, “Pharmaceutical preparations” companies have a potential upside of 99.24%. Given HCW Biologics’ stronger consensus rating and higher possible upside, analysts plainly believe HCW Biologics is more favorable than its rivals.

Volatility & Risk

HCW Biologics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, HCW Biologics’ rivals have a beta of 0.84, suggesting that their average share price is 16% less volatile than the S&P 500.

Earnings and Valuation

This table compares HCW Biologics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
HCW Biologics	$6.72 million	-$14.90 million	-3.42
HCW Biologics Competitors	$8.24 billion	$225.71 million	-3.98

HCW Biologics’ rivals have higher revenue and earnings than HCW Biologics. HCW Biologics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares HCW Biologics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HCW Biologics	N/A	-34.37%	-30.70%
HCW Biologics Competitors	-3,380.54%	-239.13%	-35.26%

Summary

HCW Biologics beats its rivals on 8 of the 13 factors compared.

HCW Biologics Company Profile

(Get Rating)

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.